Editor Name: Akiva Mintz
Country: New York
University: Columbia University Medical
Center
Designation: Professor
Department: Department of Radiology,
Division of Nuclear Medicine,
Email: am4754@cumc.columbia.edu
BIOGRAPHY:
Akiva Mintz, M.D., Ph.D, is a
physician-scientist whose translational research focuses on developing and
personalizing cancer therapies using non-invasive molecular imaging. He
obtained his medical and graduate degrees at the Pennsylvania State University College
of Medicine where he helped discover and therapeutically exploit a new cancer
restricted biomarker in malignant brain cancer. Dr. Mintz subsequently
completed a Nuclear Medicine residency and an NIH-sponsored molecular imaging
fellowship at the University of Pennsylvania, where he developed novel
preclinical multimodality imaging tools to non-invasively visualize disease and
early response to therapy. Dr. Mintz is Dual-Board Certified in Nuclear
Medicine and Clinical Informatics. In addition to his medical training, Dr.
Mintz is a CFA charterholder and completed a Masters in Healthcare
Administration (MHA) at the University of North Carolina at Chapel Hill.
Dr. Mintz is Professor of Radiology at
Columbia University Medical Center and Attending Radiologist at New York
Presbyterian Hospital. He also is Vice Chairman of Translational Research,
Director of the Kreitchman PET Center and Division Chief of the Nuclear
Medicine division. Prior to Columbia, Dr. Mintz worked at Wake Forest, where he
held a number of leadership roles, including Vice Chair of Radiology and
Section Head of Nuclear Medicine. Dr. Mintz was also the Associated Director of
the Wake Forest Clinical and Translational Science Institute and Co-leader of
the Cancer Biology and Biochemistry Program of the NCI-designated Wake Forest
Comprehensive Cancer Center.
Dr. Mintzs cross-translational research
efforts exploit nuclear-based molecular imaging and therapy techniques to
personalize anti-cancer therapies. His work is funded by multiple NIH grants
and the American Cancer Society.
Education
& Training:
MD, Pennsylvania State University
College of Medicine
PhD, Pennsylvania State University
Internship: LeHigh Valley Hospital
Residency: Hospital of the University of Pennsylvania
Publications:
1. Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya D,
Almaguel F, Wadas T, Herpai D, Debinski W, *Mintz A. IL13RA2 targeted alpha
particle therapy against glioblastoma. In Press, Oncotarget (2017).
2. Prabhakaran J, Zanderigo F, Solingapuram Sai KK, Rubin-Falcone
H, Jorgensen MJ, Kaplan JR, Mintz A, Mann JJ, Kumar D. Radiosynthesis and In
Vivo Evaluation of [11C]A1070722, a High Affinity GSK3 PET Tracer in Primate
Brain. In Press, ACS Chemical Neuroscience (2017).
3. Prazeres P, Sena I, Borges I, Azevedo P, Andreotti J,
Paiva A, Almeida V, Guerra DA, Santos G, Mintz A, Delbono O, Birbrair A.
Pericytes are heterogeneous in their origin within the same tissue (2017) in
press Developmental Biology.
4. Solingapuram Sai KK, Prabhakaran J, Sattiraju A, Mann JJ,
Mintz A, Kumar JSD. Radiosynthesis and evaluation of IGF1R PET ligand
[11C]GSK1838705A. In Press Bioorganic & Medicinal Chemistry Letters (2017).
5. Sun Y, Xiong X, Pandya D, Jung Y, Mintz
A*(corresponding), Hayasaka S, Wadas TJ, Li KC. Enhancing tissue permeability
with MRI guided preclinical focused ultrasound system in rabbit muscle: from
normal tissue to VX2 tumor. In Press Journal of Controlled Release (2017).
6. Tyrrell DJ, Bharadwaj MS , Jorgensen, MJ, Register TC,
Shively C, Andrews R, Neth B, Keene CD, Mintz A, Craft S, Molina AJA.
Blood-Based Bioenergetic Profiling Reflects Differences in Brain Bioenergetics
and Metabolism. Oxidative Medicine and Cellular Longevity. In Press (2017).
7. Gottesman RF, Schneider ALC, Zhou Y, Coresh J, Green E,
Gupta N, Knopman DS, Mintz A, Rahmim A, Sharrett AR, Wagenknecht LE, Wong DF,
Mosley TH. Association Between Midlife Vascular Risk Factors and Estimated
Brain Amyloid Deposition. JAMA (2017) 317 (14), 1443-1450.
8. Solingapuram Sai KK, Sattiraju A, Almaguel FG, Xuan A,
Rideout S, Krishnaswamy RS, Zhang J, Herpai DM, Debinski W, *Mintz A.
Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. In Press,
Oncotarget (2017).
9. Solingapuram Sai KK, Das B, Almaguel FG, Sattiraju A,
*Mintz A. Radiolabeling and initial biological evaluation of [18F]KBM-1 for
imaging RAR-α receptors in neuroblastoma. Bioorganic & Medicinal Chemistry
Letters (2017) 27 (6), 1425-1427.
10. Solingapuram Sai KK, Mintz A. Metabolic PET Imaging.
(2017) In Press, American Journal of Roentgenology (AJR).
11. Sattiraju A, Solingapuram Sai KK, Mintz A. GBM stem
cells in the tumor microenvironment. Advances in Experimental Medicine and
Biology (Springer). Accepted for Publication (2017).
12. Wang L, Habib AA, Mintz A, Li KC, Zhao D. Phosphatidylserine-targeted
nanotheranostics for brain tumor imaging and therapeutic potential. (2017) In
Press, Molecular Imaging.
13. Solingapuram Sai KK, Gage D, Neth B, Hughes, Tremblay
S., Castellano CA, Cunnane S, Jorgenson M, Kaplan J, Craft S. Mintz A*.
Automated Synthesis of [11C]acetoacetate on a TRASIS AIO module with non-human
primate whole body PET imaging. Applied Radiation and Isotopes (2016) Accepted
for publication.
14. Hu Y, Feng X, Mintz A, Petty W, Hsu W. Regulation of
brachyury by fibroblast growth factor receptor 1 in lung cancer. Oncotarget
(2016) 7:87124.
15. Prabhakaran J, Solingapuram Sai KK, Zanderigo F,
Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Tooke KI, Mintz A, Mann JJ. Kumar D.
In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT2A/2C receptor PET
radioligand in nonhuman primate Bioorganic & Medicinal Chemistry Letters
(2016) 27 (1), 21-23
16. Y Hu, R Singh, Z Deng, A Mintz, W Hsu.
Liposome-Protamine-DNA Nanoparticle-Mediated Delivery of Short Hairpin RNA
Targeting Brachyury Inhibits Chordoma Cell Growth. Journal of Biomedical
Nanotechnology (2016) 12 (10), 1952-1961.
17. Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz
A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD,
Desideri S, Ye X, Grossma SA, Schiff D, Wahl RL. Repeatability of 18F-FLT PET
in a Multi-Center Study of Patients with High Grade Glioma. (2016) Journal of
Nuclear Medicne and Moleclar Imaging 58:393-398.
18. Birbrair A, Sattiraju A, Zhu D, Zulato G, Batista I,
Nguyen VT, Messi, ML, Solingapuram Sai KK, Marini FC, Delbono O, *Mintz A.
Novel Peripherally Derived Neural-Like Stem Cells as Therapeutic Carriers for
Treating Glioblastomas (2016) Stem Cells Translational Medicine 5:1-11.
19. RF Gottesman, ALC Schneider, Y Zhou, X Chen, E Green, N
Gupta, DS Knopman, A Mintz, A Rahmim, AR Sharrett, LE Wagenknecht, DF Wong, TH
Mosley. The ARIC-PET Amyloid Imaging Study: Brain Amyloid Differences by Age,
Race, Sex, and APOE. (2016) Neurology 87 (5), 473-480.
20. Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL,
Batista I, Mintz A, Li KC, Wadas TJ. Preliminary therapy evaluation of
(225)ac-dota-c(rgdyk) demonstrates that cerenkov radiation derived from (225)ac
daughter decay can be detected by optical imaging for in vivo tumor
visualization. Theranostics. 2016;6:698-709.
21. Xiong X, Sun Y, Sattiraju A, Jung Y, Mintz A, Hayasaka
S, Li KC. Remote spatiotemporally controlled and biologically selective
permeabilization of blood-brain barrier. J Control Release. 2015; 217:113-120.
PMCID: PMC4623944.
22. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono
O. Pericytes at the intersection between tissue regeneration and pathology.
Clinical science. 2015;128:81-93.
23. Sai KKS, Gage D, Nader M, Mach RH, *Mintz A. Improved
automated radiosynthesis of [(11)C]PBR28. Sci Pharm. 2015; 83(3):413-427.
PMCID: PMC4727796.
24. Gerstner E, Zhang Z, Fink J, Muzi M, Hanna L, Greco E,
Prah M, Schmainda K, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM,
Sorensen AG, Barboriak D, Mankof DA. ACRIN 6684: Assessment of tumor hypoxia in
newly diagnosed gbm using 18F-FMISO PET and MRI. Clinical Cancer Research 22
(20), 5079-5086.
25. Tamam M, *Mintz A. Pseudoaneurysm of a pancreas
allograft artery detected by 99mtc red blood cell SPECT/CT. Clin Nucl Med.
2015;40:e241-244.
26. Wadas TJ, Pandya DN, Solingapuram Sai KK, *Mintz A.
Molecular targeted alpha-particle therapy for oncologic applications. AJR Am J
Roentgenol. 2014;203:253-260.
27. Hu Y, Mintz A, Shah SR, Quinones-Hinojosa A, Hsu W. The
fgfr/mek/erk/brachyury pathway is critical for chordoma cell growth and
survival. Carcinogenesis. 2014;35:1491-1499.
28. *Mintz, A. PET/CT in Prostate Cancer: An Unmet Clinical
Need. 2014. (Commentary) Oncology, 2014;28:1057-65. 2.
29. #Eriksson O, #Mintz A, Liu C, Yu M, Naji A, Alavi A. On
the use of [18F]FDOPA as an imaging biomarker for transplanted islet mass.
Annals of nuclear medicine. 2014;28:47-52
30. Birbrair A, Zhang T, Wang ZM, Messi ML, Olson JD, Mintz
A, Delbono O. Type-2 pericytes participate in normal and tumoral angiogenesis.
American journal of physiology. Cell physiology. 2014;307:C25-38.
31. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono
O. Pericytes: Multitasking cells in the regeneration of injured, diseased, and
aged skeletal muscle. Frontiers in aging neuroscience. 2014;6:245.
32. Birbrair A, Zhang T, Files DC, Mannava S, Smith T, Wang
ZM, Messi ML, Mintz A, Delbono O. Type-1 pericytes accumulate after tissue
injury and produce collagen in an organ-dependent manner. Stem cell research
& therapy. 2014;5:122.
33. Kota G, Gupta P, *Mintz A. PET/CT illustration of
metastatic breast cancer to the left mandibular foramen. Clin Nucl Med.
2013;38:385-386.
34. Kota G, Gupta P, Lesser GJ, Wilson JA, Mintz A.
Somatostatin receptor molecular imaging for metastatic intracranial
hemangiopericytoma. Clin Nucl Med. 2013;38:984-987.
35. Deford-Watts LM, Mintz A, Kridel SJ. The potential of
(1)(1)c-acetate PET for monitoring the fatty acid synthesis pathway in tumors.
Current pharmaceutical biotechnology. 2013;14:300-312.
36. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono
O. Type-1 pericytes participate in fibrous tissue deposition in aged skeletal
muscle. American journal of physiology. Cell physiology. 2013;305:C1098-1113.
37. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN,
Mintz A, Delbono O. Skeletal muscle neural progenitor cells exhibit properties
of ng2-glia. Exp Cell Res. 2013;319:45-63.
38. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN,
Mintz A, Delbono O. Skeletal muscle pericyte subtypes differ in their
differentiation potential. Stem Cell Res. 2013;10:67-84.
39. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN,
Mintz A, Delbono O. Role of pericytes in skeletal muscle regeneration and fat
accumulation. Stem Cells Dev. 2013;22:2298-2314.
40. Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson
SM, Debinski W, *Mintz A. A novel ligand delivery system to non-invasively
visualize and therapeutically exploit the IL13ralpha2 tumor-restricted
biomarker. Neuro Oncol. 2012;14:1239-1253.
41. Gupta P, Kota G, *Mintz A. Evolution of a ureteric stone
from the renal pelvis to the ureter on skeletal scintigraphy with ct
correlation. Clin Nucl Med. 2012;37:188-189.
42. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J,
Debinski W. Ephrina1 is released in three forms from cancer cells by matrix
metalloproteases. Mol Cell Biol. 2012;32:3253-3264.
43. Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF,
Debinski W, *Mintz A. IL-13ralpha2-targeted therapy escapees: Biologic and
therapeutic implications. Transl Oncol. 2011;4:390-400.
44. Gupta P, Kota G, Alavi A, *Mintz A. Unilateral diffusely
increased muscle uptake of f-18 fdg in a patient with hemiparesis due to
stroke. Clin Nucl Med. 2011;36:1140-1141.
45. Nguyen V, Conyers JM, *Mintz A. Pretargeting the masses:
A means of improving and mainstreaming targeted molecular delivery? Cancer Biol
Ther. 2010;10:775-779.
46. Kota GK, Gupta P, Conyers JM, *Mintz A. Targeting
angiogenesis in an age of personalized medicine. Cancer Biol Ther.
2010;10:874-877.
47. Nguyen V, *Mintz A. New frontiers in biomarker-targeted
molecular imaging. Cancer Biol Ther. 2009;8:2248-2251.
48. Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP,
Dicker DT, Kao GD, El-Deiry WS. Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo
effects against glioblastoma multiforme cells. Mol Cancer Ther.
2009;8:3285-3295.
49. Mintz A, Gibo DM, MadhanKumar AB, Cladel NM, Christensen
ND, Debinski W. Protein- and DNA-based active immunotherapy targeting
interleukin-13 receptor alpha2. Cancer Biotherapy & Radiopharmaceuticals.
2008;23:581-589.
50. Mintz A, Wang L, Ponde DE. Comparison of radiolabeled
choline and ethanolamine as probe for c.
For more
Article:Â
https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48686629/?sort=date&direction=ascending